Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? pps

... Rea-Neto A, et al. for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (acti- vated) for adults with severe sepsis and a ... number of patients randomly assigned to drotrecogin alfa (activated) or placebo. For the phase II trial, only patients who were randomized to the same dose and duration o...

Ngày tải lên: 12/08/2014, 23:24

... event rates for both active treatment and placebo patients enrolled in clinical trials of drotrecogin alfa (activated) probably underestimate the bleeding risk for all patients with severe sepsis. ... administer drotrecogin alfa (activated) to patients with platelet counts of 30,000/mm 3 or less. Indeed, serious bleeding events in drotrecogin alfa (activated) pa...

Ngày tải lên: 12/08/2014, 19:22

... not for citation purposes) Critical Care Vol 10 No 5 Williams et al. References 1. Friedrich JO, Adhikari NKJ, Meade MO: Drotrecogin alfa (acti- vated): does current evidence support treatment for ... Rea-Neto A, et al., for the Administration of Drotrecogin alfa (activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (acti- vated) for...

Ngày tải lên: 13/08/2014, 03:20

... JT, Sundin DP, Levi M: Treatment effects of drotrecogin alfa (acti- vated) in patients with severe sepsis with or without overt dis- Key messages • Patients with severe sepsis with signs and symptoms ... the management of adult patients with severe sepsis with evidence of PF, MEN, or MD • DrotAA is not currently approved for treatment of pedi- atric patien...

Ngày tải lên: 12/08/2014, 22:21

... MA, Janes J: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. ... guidelines for severe sepsis and septic shock, under the auspices of the Surviving Sepsis Campaign [7]. Though DrotAA is an important drug with well-documented beneficial effec...

Ngày tải lên: 13/08/2014, 03:20

Ngày tải lên: 13/08/2014, 03:20

... (indicating no effect for lower ICNARC physiology scores and for patients with two organs failing, as compared with a significant reduc- tion in mortality for higher scores and for patients with three or more ... the critical care unit for an admission with severe sepsis was 8 days, as compared with around 3.5 days for other admis- sions. Admissions with severe...

Ngày tải lên: 13/08/2014, 10:20

... countries. ADDRESS consisted of patients with severe sepsis at low risk of death not indicated for treatment with DrotAA. PROWESS consisted of patients with severe sepsis with one or more organ dysfunctions. ... purposes) Mortality for patients experiencing any bleeding event in ADDRESS was higher than for patients not experiencing a bleeding complication, irresp...

Ngày tải lên: 13/08/2014, 11:22

... MA, Janes J: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: fur- ther evidence for survival and safety and implications for early treatment. Crit ... all patients who received DrotAA for severe sepsis with two or more organs in failure and with acute kidney injury requiring RRT between 2002 and 2006. The selection of...

Ngày tải lên: 13/08/2014, 11:23

... http://ccforum.com/content/13/1/113 Page 1 of 2 (page number not for citation purposes) Abstract In a retrospective study among 35 severely septic patients treated with drotrecogin alfa (activated) ... requirements among 35 severely septic patients treated with drotrecogin alfa (activated) (DrotAA) and renal replacement therapy (RRT). DrotAA is capable of reducing mortality...

Ngày tải lên: 13/08/2014, 11:23